- Home
- LE vs DBVT Comparison
LE vs DBVT Comparison
Compare LE & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LE
- DBVT
- Stock Information
- Founded
- LE 1963
- DBVT 2002
- Country
- LE United States
- DBVT France
- Employees
- LE N/A
- DBVT N/A
- Industry
- LE Clothing/Shoe/Accessory Stores
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LE Consumer Discretionary
- DBVT Health Care
- Exchange
- LE Nasdaq
- DBVT Nasdaq
- Market Cap
- LE 274.7M
- DBVT 259.8M
- IPO Year
- LE N/A
- DBVT N/A
- Fundamental
- Price
- LE $9.47
- DBVT $11.10
- Analyst Decision
- LE Strong Buy
- DBVT Strong Buy
- Analyst Count
- LE 1
- DBVT 3
- Target Price
- LE $20.00
- DBVT $13.67
- AVG Volume (30 Days)
- LE 131.5K
- DBVT 103.2K
- Earning Date
- LE 06-04-2025
- DBVT 04-30-2025
- Dividend Yield
- LE N/A
- DBVT N/A
- EPS Growth
- LE N/A
- DBVT N/A
- EPS
- LE 0.20
- DBVT N/A
- Revenue
- LE $1,362,935,000.00
- DBVT $3,497,000.00
- Revenue This Year
- LE $4.26
- DBVT $1,700.53
- Revenue Next Year
- LE $2.67
- DBVT $535.67
- P/E Ratio
- LE $47.52
- DBVT N/A
- Revenue Growth
- LE N/A
- DBVT N/A
- 52 Week Low
- LE $8.15
- DBVT $0.44
- 52 Week High
- LE $19.88
- DBVT $9.90
- Technical
- Relative Strength Index (RSI)
- LE 55.38
- DBVT 71.88
- Support Level
- LE $7.65
- DBVT $10.56
- Resistance Level
- LE $9.47
- DBVT $12.78
- Average True Range (ATR)
- LE 0.44
- DBVT 0.80
- MACD
- LE 0.19
- DBVT 0.10
- Stochastic Oscillator
- LE 94.30
- DBVT 59.90
About LE Lands' End Inc.
Lands' End Inc is a United States-based multi-channel retailer of casual clothing, accessories, and footwear, as well as home products. The company's operating segment includes U.S. eCommerce; International; Outfitters; Third Party and Retail. It generates maximum revenue from the U.S. eCommerce segment. The U.S. eCommerce segment offers products through the company's eCommerce website. Geographically, it derives a majority of its revenue from the United States.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.